This study investigates the acceptability of detecting circulating tumor deoxyribonucleic acid (ctDNA) in patients with humanpapilloma virus (HPV) associated anal and cervical cancers, that are on definitive radiation therapy. Circulating tumor DNA (ctDNA) is found in the bloodstream and refers to deoxyribonucleic acid (DNA) that comes from broken down or dead cancerous cells and tumors. Detection of ctDNA may be helpful in detecting and diagnosing a tumor, assessing the treatment response, and subsequently disease status in patients with anal and cervical cancers.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04857528.
Locations matching your search criteria
United States
Illinois
Chicago
University of Chicago Comprehensive Cancer CenterStatus: Active
Contact: Christina Huijin Son
Phone: 312-996-7379
PRIMARY OBJECTIVE:
I. Determine whether HPV DNA can be detected in specimens obtained prior to or during treatment.
SECONDARY OBJECTIVES:
I. Calculate accuracy of 3-month HPV DNA in predicting recurrence.
II. Evaluate the performance of circulating HPV DNA in detecting recurrence.
EXPLORATORY OBJECTIVE:
I. Evaluate change in HPV DNA over course of treatment and at early follow-up time points.
OUTLINE: This is an observational study.
Patients undergo collection of blood samples for ctDNA detection throughout the study.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationUniversity of Chicago Comprehensive Cancer Center
Principal InvestigatorChristina Huijin Son
